ClinicalTrials.gov: HTL9936 (Phase 1b: 9936-104, NCT02710188): Estimated Study Completion: September 2016 (Primary: August). → ※This study has been completed (Completion: August, Primary: July.). (10/17 update)
※Drug Profile: HTL9936 (Phase 1b: 9936-104, NCT02710188): 01 Aug 2016, Heptares Therapeutics completes a phase I trial in Cognition disorders in UK. (10/24 update)
※ClinicalTrials.gov: Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules. 11/4 update (11/8)
・(Phase 1: 18318-104 NCT02958696, Recruiting, Study Start Date: October 2016, Estimated Study Completion Date: December 2016)
※Drug Profile: HTL18318. (11/10 update)
ClinicalTrials.gov: HTL9936 (Phase 1b: 9936-104, NCT02710188): Estimated Study Completion: September 2016 (Primary: August). → ※This study has been completed (Completion: August, Primary: July.). (10/17 update)
※Drug Profile: HTL9936 (Phase 1b: 9936-104, NCT02710188): 01 Aug 2016, Heptares Therapeutics completes a phase I trial in Cognition disorders in UK. (10/24 update)
※ClinicalTrials.gov: Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules. 11/4 update (11/8)
・(Phase 1: 18318-104 NCT02958696, Recruiting, Study Start Date: October 2016, Estimated Study Completion Date: December 2016)
※Drug Profile: HTL18318. (11/10 update)